

Asco 2021 story roundup



[Jacob Plieth](#)

Though formally this year's Asco conference kicked off on Friday, all the session abstracts and presentations, including late-breakers, had already been made available either on its virtual platform or at special press briefings. So far *Evaluate Vantage* has covered the following stories from the meeting:

June 9:

[*Asco 2021 movers - PDS wins, but big pharma reigns*](#)

June 7:

[*The exon 20 army lines up behind Rybrevant*](#)

June 4:

[*Alpine hopes to banish the ghost of Tegenero*](#)

[*Merus's slight improvement might not win over investors*](#)

[*Alkermes's disappointment hones melanoma niche focus*](#)

June 3:

[*Bristol makes more progress in stomach cancer*](#)

[*Financial toxicity in the spotlight*](#)

[*Full Olympia results sweep away Parp doubts*](#)

[*Asco 2021 justifies Novartis's radioligand Vision*](#)

[*Keytruda's adjuvant kidney win is the real deal*](#)

May 21:

[*Abstract lift drives first stock moves*](#)

May 20:

[*Off-the-shelf cell therapy inches towards reality*](#)

[*Merus intrigues in pancreatic cancer*](#)

[*Guardant shoots for the moon*](#)

May 19:

[*Adaptimmune's T-cell receptors see a route to market*](#)

[*Bristol's Lag3 case for a replacement for Yervoy*](#)

[*Adjuvant lung cancer beckons for Tecentriq, but only in PD-L1 expressers*](#)